Breaking News
December 18, 2018 - Getting the Most Out of the CLARITY Technique
December 18, 2018 - NVF shoes provide a viable option for track and road racing
December 18, 2018 - CRISPR may restore effectiveness of chemotherapies used to treat lung cancer
December 18, 2018 - New app accurately measures and charts progression of skin wounds
December 18, 2018 - Persistent Discrimination ID’d Among Physician Mothers
December 18, 2018 - Cellphone technology developed to detect HIV
December 18, 2018 - A Stanford doctor hits the field with the 49ers — as their airway management physician
December 18, 2018 - The Rise of Anxiety Baking
December 18, 2018 - Just one night of sleep deprivation increases the urge to eat
December 18, 2018 - Study reveals mechanism behind failed remyelination in MS
December 18, 2018 - New genetic testing method increases the precision of biomarker analysis
December 18, 2018 - Simple technique to effectively treat underdiagnosed cause of debilitating chest pain
December 18, 2018 - Barbershop-based medical intervention can successfully lower blood pressure, new data shows
December 18, 2018 - Food labels have caused changes in consumers’ intake and industry’s use of key additives
December 18, 2018 - Sickest children could benefit from split liver transplants
December 18, 2018 - Scientists create patient-specific model to identify most effective treatment for appendix cancer
December 18, 2018 - Researchers discover promising new compound against Buruli ulcer
December 18, 2018 - Study finds significant use of traditional, complementary and alternative medicines in Sub-Saharan Africa
December 18, 2018 - California Farm Implicated in Outbreak of E. coli Tied to Romaine Lettuce
December 18, 2018 - Mobile health has power to transform HIV/AIDS nursing
December 18, 2018 - Celiac Vaccine in Clinical Trials at Columbia
December 18, 2018 - Research into mental health first aid prompts practical guidance and resources for workplace
December 18, 2018 - Researcher conducts study to investigate peripheral blood markers of Alzheimer’s disease
December 18, 2018 - Researchers identify link between mucus in the small airways and pulmonary fibrosis
December 18, 2018 - EU Commission’s Health Policy Platform to host EKHA program on transplantation
December 18, 2018 - Survivors of childhood Hodgkin lymphoma have high risk of developing solid tumors
December 18, 2018 - Small changes to cafeteria design can get kids to eat healthier, new assessment tool finds
December 18, 2018 - From Machines to Cyclic Compounds
December 18, 2018 - New study reveals best assessment tools to establish delirium severity
December 18, 2018 - Rice University scientists develop synthetic protein switches to control electron flow
December 18, 2018 - Home-based pulmonary function monitoring for teens with Duchenne muscular dystrophy
December 18, 2018 - Researchers identify potential target for new breast cancer treatments
December 18, 2018 - National Biofilms Innovation Centre award grant to Neem Biotech for novel anti-biofilm drug development
December 18, 2018 - Artificial intelligence and the future of medicine
December 18, 2018 - Montana State doctoral student receives grant for her work to improve neuroscience tool
December 18, 2018 - Early postpartum initiation of opioids associated with persistent use
December 18, 2018 - Russian scientists identify molecular ‘switch’ that could be target for treatment of allergic asthma
December 18, 2018 - Surgeons make more mistakes in the operating room during stressful moments, shows study
December 18, 2018 - Immune cells explode themselves to inform about the danger of invading bacteria
December 18, 2018 - Malnutrition in children with Crohn’s disease linked with increased risk of surgical complications
December 18, 2018 - FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)
December 18, 2018 - The long and short of CDK12
December 18, 2018 - Hologic’s Cynosure division introduces TempSure Surgical RF technology in North America
December 18, 2018 - CMR Surgical partners with Nicholson Center to launch U.S.-based training program for Versius
December 18, 2018 - Findings reinforce guidelines for cautious use of antipsychotics in younger populations
December 18, 2018 - Study finds new strains of hepatitis C virus in sub-Saharan Africa
December 18, 2018 - New battery-free, implantable device aids weight loss
December 18, 2018 - Parental alcohol use disorder associated with offspring marital outcomes
December 18, 2018 - Novel Breast Imaging Technique Might Cut Unnecessary Biopsies
December 18, 2018 - What can a snowflake teach us about how cancer spreads in the body?
December 18, 2018 - Management of nausea and vomiting in pregnancy costs the NHS more than previously thought
December 18, 2018 - Green leafy vegetables may reduce risk of developing liver steatosis
December 18, 2018 - Veganism linked to nutrient deficiencies and malnutrition if not planned correctly
December 18, 2018 - Coming Soon: A Tiny Robot You Swallow to Help You Stay Healthy
December 18, 2018 - Modified malaria drug proven effective at inhibiting Ebola
December 18, 2018 - Study finds epigenetic differences in the brains of individuals with schizophrenia
December 18, 2018 - Fitness instructors’ motivational comments influence women’s body satisfaction
December 18, 2018 - Study focuses on modification of lipid nanoparticles for successful brain cell targeting
December 18, 2018 - New gut bacteria may be effective against obesity, metabolic and mental disorders
December 18, 2018 - New two-in-one powder aerosol to upgrade fight against deadly superbugs in lungs
December 18, 2018 - Biofilms feed with swirling flows
December 17, 2018 - Study identifies specific neurological changes related to traumatic brain injury
December 17, 2018 - New study confirms geographic bias in lung allocation for transplant
December 17, 2018 - Research focuses on optimization of solid lipid nanoparticle that encapsulates Vinorelbine bitartrate
December 17, 2018 - Carpal tunnel syndrome – Genetics Home Reference
December 17, 2018 - A novel insulin accelerant
December 17, 2018 - Tips for caring for patients with disabilities, from a mother and physician
December 17, 2018 - Menopause-related sexual, urinary problems tied to worse quality of life
December 17, 2018 - In-school nutrition programs among students limit increases in BMI, finds study
December 17, 2018 - Risk for Hospitalization for Heart Failure Greater With Diabetes
December 17, 2018 - Food assistance may help older adults adhere to diabetes meds
December 17, 2018 - Supporting a family’s goals during a difficult pregnancy
December 17, 2018 - Neurons with Good Housekeeping Are Protected from Alzheimer’s
December 17, 2018 - New approach to tumor analysis could improve prognosis for bowel cancer patients
December 17, 2018 - New ‘epigenetics-based’ cervical cancer test outperforms Pap smear and HPV tests
December 17, 2018 - Ten year follow-up after negative colonoscopy related to reduced risk of colorectal cancer
December 17, 2018 - CTF along with NTAP and Sage announce first-ever open data portal for neurofibromatosis
December 17, 2018 - Intimacy: The Elusive Fountain of Youth?
December 17, 2018 - Will saliva translate to a real diagnostic tool?
December 17, 2018 - DFG establishes nine new Research Units and one new Clinical Research Unit
Esketamine Nasal Spray Eases Depression Quickly

Esketamine Nasal Spray Eases Depression Quickly

image_pdfDownload PDFimage_print

Action Points

  • Note that this small randomized trial demonstrated that an intranasal formulation of the s-enantiomer of ketamine had strong anti-depressant effects compared to placebo.
  • Be aware that individuals with psychotic symptoms or a history of psychosis were excluded as the drug could potentiate these symptoms.

An intranasal formulation of ketamine quickly diminished depressive symptoms in patients with treatment-resistant depression, researchers found.

In a phase II study, those taking one of three doses of esketamine (28 mg, 56 mg, or 84 mg) had significantly greater improvement in Montgomery-Asberg Depression Rating Scale (MADRS) scores compared with placebo over 8 days, Ella Daly, MD, of Janssen, and colleagues reported online in JAMA Psychiatry.

Those improvements persisted despite reduced dosing frequency in a subsequent open-label phase that lasted about two months, the researchers said.

Several studies have shown ketamine to have antidepressant effects, and there’s been growing interest in this and other NMDA receptor antagonists, in the class of glutamate receptor modulators, to treat depression and suicidality — especially since about a third of patients don’t respond to current treatment options.

A limitation of ketamine, however, is that it needs to be delivered intravenously. So researchers at Janssen developed an intranasal formulation called esketamine, which is the S-enantiomer of ketamine. This version has a higher affinity for the NMDA receptor than the ketamine R-enantiomer, the researchers explained, adding that nasal delivery will also boost bioavailability of the compound. (The chirally pure molecule can also be patented separately from the racemic form.)

The current study enrolled patients at multiple outpatient referral centers from January 2014 to September 2015. It involved four phases: screening; double-blind treatment (days 1-15) composed of two one-week periods; optional open-label treatment (days 15-74); and post-treatment follow-up (8 weeks).

This design allowed for a smaller sample size to assess efficacy, dose-response, and safety than a standard parallel-group design, while preserving a low chance of type 2 error to avoid missing the efficacy signal, the researchers said.

A total of 67 patients (mean age 45) were randomized, and 60 completed both double-blind periods. All had treatment-resistant depression, which was defined as a lack of clinically meaningful improvement after treatment with at least two different oral antidepressants taken at adequate doses. All of them continued to take their oral antidepressants during the study, and esketamine nasal spray was delivered under the supervision of a healthcare professional.

In the first period, participants were randomized to placebo or to one of the three doses of esketamine. In the second phase, 28 placebo-treated patients with moderate-to-severe symptoms were re-randomized to one of the four treatment arms, while those with mild symptoms continued to receive placebo. Finally, during the open-label phase, dosing frequency was reduced from twice weekly to weekly, then to every two weeks.

The primary efficacy endpoint was change from baseline to 8 days on the MADRS scale.

Overall, Daly and colleagues found that the anti-depressant effect was rapid in onset, evident as early as two hours post-dose, and was dose-related. Mean MADRS scores fell in all groups, with significantly greater improvement in all esketamine dose groups compared with placebo, as well as a dose-response relationship.

  • 28 mg: −4.2, P=0.02
  • 56 mg: −6.3, P=0.001
  • 84 mg: −9.0, P<0.001

These improvements persisted over 8 weeks of follow-up without additional esketamine doses in those who remained in the study, the researchers added. Responses “appeared to persist for more than two months with a lower dosing frequency,” they wrote.

During the double-blind phase, the most common treatment-emergent adverse events in esketamine-treated patients were dizziness, headache, and dissociative symptoms. (The latter has been a problem with racemic ketamine; the quasi-hallucinatory effect has made it a drug of abuse, with street names such as Special K.)

Three of 56 esketamine-treated patients discontinued the study during the blinded phase, as did one of 57 patients during the open-label phase. These included one event each of syncope, headache, dissociative syndrome, and ectopic pregnancy. None of the placebo-treated patients discontinued.

Most esketamine-treated patients had transient elevations in blood pressure and heart rate on dosing days, which returned to normal within two hours of the dose. Perceptual changes or dissociative symptoms began shortly after the start of intranasal dosing, peaked at 30 to 40 minutes, and similarly resolved by two hours. These effects attenuated in all dose groups with repeated dosing, and there was no psychosis.

Daly and colleagues concluded that the results support further investigation in larger trials, and the drug is currently being evaluated in phase III trials in treatment-resistant depression and for patients with major depressive disorder who are at immediate risk for suicide.

In an accompanying editorial, Ole Andreassen, MD, PhD, of Oslo University, and colleagues said the significant effects at just one week are “substantially faster than current treatments.”

While esketamine is a good candidate for intranasal delivery, they wrote, some potential barriers include mucosal inflammation, nasal polyps, and septal deviation. Poor self-administration practices can also reduce efficacy, they noted.

Although there was no psychosis in the trial, patients with psychotic disorders or major depressive disorder with psychosis were excluded, Andreassen and colleagues cautioned. They also urged that “the potential for addiction” be evaluated in future studies.

Still, they said the results demonstrate “considerable promise of combining a compound with rapid antidepressant effects with intranasal delivery” and await results from phase III results.

Several authors are employees of Janssen, which funded the study.

The editorialists disclosed financial relationships with Lundbeck and being co-inventors on an intranasal oxytocin delivery device.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-12-28T16:30:00-0500

Tagged with:

About author

Related Articles